Johnson and Johnson completes acquisition of Actelion

Johnson and Johnson has announced the completion of its acquisition of the pharmaceutical company Actelion.

The $30 billion (23.49 billion pounds) deal sees Actelion become part of the Janssen pharmaceuticals portfolio, strengthening its offering of therapies for pulmonary arterial hypertension and other serious illnesses.

Actelion's pulmonary arterial hypertension franchise includes differentiated innovative medicines such as Opsumit, Uptravi and Tracleer, and establishes a sixth therapeutic area as a growth engine for Janssen.

As part of the terms of the deal, Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company called Idorsia.

Johnson and Johnson expects the transaction to add approximately $1.3 billion in sales to its bottom line for 2017.

Alex Gorsky, chairman and chief executive officer of Johnson and Johnson, said: "We are excited to welcome our new Actelion colleagues to the Johnson and Johnson family of companies as we work together to improve the health of people around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.